Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States by Padula, William V. et al.
Received: May 8, 2015; Revised: September 9, 2015; Accepted: January 6, 2016
© The Author 2016. Published by Oxford University Press.
JNCI J Natl Cancer Inst (2016) 108(7): djw003
doi:10.1093/jnci/djw003
First published online March 4, 2016
Article
1 of 9
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, 
provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
a
r
t
ic
le
article
Cost-effectiveness of Tyrosine Kinase Inhibitor 
Treatment Strategies for Chronic Myeloid Leukemia 
in Chronic Phase After Generic Entry of Imatinib in 
the United States
William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, 
Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, 
Francois Guilhot, Rudiger Hehlmann, Francois-Xavier Mahon, 
Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, 
Susanne Saussele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, 
Rena M. Conti
Affiliations of authors: Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP); Department of Medicine (RAL) and 
Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL; Eshelman School of Pharmacy and Gillings School of Global 
Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC 
(SBD); Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA); Department of Medicine (RH, SS) and Department of Hematology 
and Oncology (MCM), University of Heidelberg, Mannheim, Germany; Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and 
Department of Hematology, “L. e A. Seragnoli” (GM), University of Bologna, Bologna, Italy; Department of Haematology and Oncology, University Hospital, Jena, 
Germany (EE); INSERM Centre d’Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG); Laboratoire d’Hematologie, Universite Victor Segalen, 
Bordeaux, Pessac, France (FXM); Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM); Department of 
Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN); Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS); 
Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS); Uppsala University, Uppsala, Sweden (BS).
Correspondence to: Rena M. Conti, PhD, 5841 S. Maryland Ave, Chicago, IL 60637 (e-mail: rconti@peds.bsd.uchicago.edu).
Abstract
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) 
with generic imatinib when it becomes available in United States in 2016. In the year following generic entry, imatinib’s 
price is expected to drop 70% to 90%. We hypothesized that initiating treatment with generic imatinib in these patients 
and then switching to the other tyrosine-kinase inhibitors (TKIs), dasatinib or nilotinib, because of intolerance or lack of 
effectiveness (“imatinib-first”) would be cost-effective compared with the current standard of care: “physicians’ choice” of 
initiating treatment with any one of the three TKIs.
Methods: We constructed Markov models to compare the five-year cost-effectiveness of imatinib-first vs physician’s 
choice from a US commercial payer perspective, assuming 3% annual discounting ($US 2013). The models’ clinical 
endpoint was five-year overall survival taken from a systematic review of clinical trial results. Per-person spending 
on incident CML-CP treatment overall care components was estimated using Truven’s MarketScan claims data. 
The main outcome of the models was cost per quality-adjusted life-year (QALY). We interpreted outcomes based 
on a willingness-to-pay threshold of $100 000/QALY. A panel of European LeukemiaNet experts oversaw the study’s 
conduct.
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Results: Both strategies met the threshold. Imatinib-first ($277 401, 3.87 QALYs) offered patients a 0.10 decrement in QALYs 
at a savings of $88 343 over five years to payers compared with physician’s choice ($365 744, 3.97 QALYs). The imatinib-
first incremental cost-effectiveness ratio was approximately $883 730/QALY. The results were robust to multiple sensitivity 
analyses.
Conclusion: When imatinib loses patent protection and its price declines, its use will be the cost-effective initial treatment 
strategy for CML-CP.
The BCR-ABL1 tyrosine kinase inhibitor (TKI) imatinib (Gleevec, 
Glivec, Novartis International AG) was approved by the US Food and 
Drug Administration (FDA) in 2001 to treat incident Philadelphia 
chromosome–positive (Ph+) chronic myeloid leukemia in chronic 
phase (CML-CP) and has been shown to produce a high cumula-
tive incidence of complete cytogenetic responses (CCyR) (1–3). 
Imatinib is also associated with improved survival. After eight 
years, the overall survival (OS) on the International Randomized 
Study of Interferon vs STI571 (imatinib) (the IRIS trial) was 85% for 
patients treated with imatinib, and their freedom from progres-
sion to accelerated phase or blast crisis (AP/BC) was 92% (4).
In the past decade, additional TKIs have demonstrated efficacy 
for treating incident CML-CP (5). Dasatinib (Sprycel, Bristol-Myers 
Squibb) and nilotinib (Tasigna, Novartis Oncology) were granted 
first-line approval for the treatment of CML-CP by the FDA. These 
“second-generation” TKIs have been compared prospectively with 
imatinib individually but not with each other in incident CML-CP 
patients (6–9). The second-generation TKIs produce more rapid 
molecular responses than imatinib at standard doses of 400 mg 
daily, but five-year OS does not differ between the three TKIs (5–9). 
Most incident CML-CP patients will require life-long, daily TKI-
based care (5–10).
In the United States, Novartis’ composition-of-matter pat-
ent on imatinib was scheduled to expire in the first quarter of 
2015. An agreement between Novartis and Sun Pharmaceutical 
Industries, Ltd., has deferred generic entry to the first quarter of 
2016. Generic imatinib is already available in Canada. For most 
European Union member countries, Novartis’ patent will also 
expire in 2016.
Health system spending on incident CML-CP after generic 
imatinib becomes available is the subject of great interest 
among patients, physicians, and payers (11,12). Loss of patent 
exclusivity opens the market to potential competition from 
multiple manufacturers. The extent of payers’ savings gained 
from a drug’s generic entry largely depends on whether and to 
what extent prices decline (13). In Canada, the price of generic 
imatinib is now 18% to 26% of the branded drug price, and man-
datory generic imatinib-first and brand-to-generic substitution 
policies have resulted in cost savings (14,15).
Physicians’ willingness to prescribe generic drugs is related 
to patient benefit, including differences in OS and quality-
adjusted life-years (QALYs). Generic drug quality may also be a 
concern, which is in part determined by the strength of indi-
vidual country drug safety regulations and permeability to drug 
importation from countries with weaker drug quality standards 
(16). Anecdotal concerns have been raised that the bioavail-
ability and potency of generic imatinib is not equivalent to the 
branded drug, based on individual case reports and small case 
series; however, a recent meta-analysis concluded that these 
concerns in non-Western countries were unfounded in Canada 
(17).
The objective of this study was to estimate the five-year 
cost-effectiveness of treating all incident CML-CP patients with 
generic imatinib as first-line therapy when it becomes available 
in 2016 in the United States from a commercial payer’s perspec-
tive compared with the current standard of care.
Methods
We hypothesized that initiating treatment among incident 
CML-CP patients in 2016 with generic imatinib and then switch-
ing as needed clinically to dasatinib or nilotinib would be cost-
effective over a five-year time horizon in comparison with the 
current standard of care, a physician’s choice of starting any one 
of the three approved TKIs and then switching to another TKI 
if the initial selection lacked efficacy or was not tolerated. Our 
study took the US commercial payer perspective because these 
insurers are the largest domestic payers of TKI-based therapy 
among CML-CP patients, including those insured through the 
fee-for-service Medicare pharmacy benefit (the “Part D”) pro-
gram, those who are insured through employer-sponsored plans, 
and those who are self-insured. The five-year time horizon was 
chosen to reflect available published data on relevant clinical 
outcomes associated with CML-CP treatment with the three 
TKIs. The methods used were based on guidelines set by the US 
Panel on Cost-Effectiveness in Health and Medicine (18). A panel 
of CML experts, all members of the European LeukemiaNet (ELN) 
CML committee, designed this study, identified the study’s main 
outcomes from a systematic review of published randomized 
clinical trials, reviewed preliminary results, and made edits to 
the manuscript to improve interpretation for a clinical audience. 
The University of Chicago Institutional Review Board approved 
this study as exempt human-subject research.
Effectiveness
The main outcome measure of the analysis was predicted OS in 
2021 among CML-CP patients initiating TKI treatment in 2016. 
For each TKI, data on actual OS were extracted from the pub-
lished clinical trials (IRIS, ENESTnd, DASISION, and second-line 
phase II/III and transplant studies) that formed the basis for reg-
ulatory approval of the TKIs for these indications (1–4,6–9,17–21).
The ELN guidelines recommend that CML-CP patients switch 
initial TKI choice if they do not experience sufficient treatment 
efficacy or tolerance (22,23). In clinical practice, treatment effi-
cacy among CML-CP patients initiating TKI treatment is moni-
tored using two distinct measures and associated time points: 
1) the achievement of a 12-month CCyR or 2) the achievement 
of a three-month early molecular response (EMR) defined as a 
reduction in BCR-ABL1 transcript levels to less than 10% com-
pared with a standardized baseline (using the International 
Scale [IS]) (5,24,25). For each TKI, predicted achievement of CCyR 
and EMR as well as tolerance data were extracted from the pub-
lished clinical trials cited above and overseen by the ELN expert 
panel (1–4,6–9,17–21).
OS, CCyR, and EMR have been associated with increased 
treatment effectiveness among CML-CP patients. Effectiveness 
was measured in units of quality-adjusted life-years based on 
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US societal CML-specific preferences reported by Szabo et  al. 
(Table 1) (26). All QALYs were discounted at 3% per year.
In rare cases, CML-CP progresses to AP/BC despite patient 
treatment with a TKI. Allogeneic hematopoietic cell transplan-
tation is indicated for the majority of these patients. The prob-
abilities of patient disease progression after initial treatment 
with a TKI and the outcome of subsequent transplantation were 
extracted from the available clinical trial literature (Table 1) (29). 
Societal QALYs associated with transplantation were extracted 
from Szabo et al. (26).
Costs
Direct medical costs per patient, per month of overall care com-
ponents were estimated using 2011 and 2012 Truven Health 
Analytics MarketScan (Truven Health, Ann Arbor, MI) commer-
cial claims and encounters data (Table  2) (14,30). These data 
represent the medical care experienced by employees and their 
dependents enrolled in commercial health insurance plans 
sponsored by approximately 100 payers, representing more 
than 50 million covered lives annually. Marketscan data are 
well studied, and we used the claims that were the basis of pre-
viously published reports of the direct costs of domestic CML 
treatment (29).
Direct medical costs were estimated among patients who 
closely reflected the inclusion criteria of the IRIS, ENESTnd, 
and DASISION trials using variables reported in the MarketScan 
data (age 18–65 years), primary diagnosis of CML (International 
Classification and Diseases, 9th revision [ICD-9], codes 205.1, 
205.8, 205.9, 207.8, 208.1, 208.8, and 208.9) with incident disease 
(newly diagnosed CML between January 1, 2011, and December 
31, 2012)  and no comorbidities. Costs were estimated among 
these patients who were treated with imatinib, dasatinib, or 
nilotinib. For identifying incident cases, the first observed TKI 
dispensing date was considered the index drug date. Patients 
were excluded if diagnosed with acute leukemia (lympoid or 
myeloid; ICD-9 codes 204 and 205.0) or were not continuously 
enrolled between three months before through 12 months after 
the index date of drug dispensing.
Costs included in the models were mean monthly CML drug 
costs for imatinib, dasatinib, and nilotinib and mean monthly 
costs for other prescription drugs, diagnostic tests and labora-
tory monitoring, outpatient visits, and hospitalizations (Table 2). 
Allogeneic transplantation was not observed in the Marketscan 
cohort. Therefore, the costs of allogeneic transplantation were 
extracted from Preussler et al. (Table 3) (30). The frequency of use 
of specific care components and the contribution of these compo-
nent costs to total per-person, per-month spending were reviewed.
The model evaluated the per-patient, per-month cost trajec-
tory of imatinib before and after patent expiration based on can-
cer drug–specific cost trajectories after generic entry recently 
published by Conti and Berndt (14,33). These trajectories were 
consistent with previously published studies, as well as contem-
poraneous Canadian trends in the per-patient, per-month costs 
following generic entry among oral drugs (14,34–37). The per-
patient, per-month cost trajectory of imatinib-based therapy uti-
lized in this study is as follows: 1) 100% of the branded treatment 
cost prior to generic entry for the first six months; 2) 60% to 80% 
for the second six months following generic entry; and 3) 10% to 
30% thereafter. The midpoint of these ranges was taken for each 
time period. Only drug-specific costs were assumed to change 
after the generic entry of imatinib; the frequency of use and the 
costs of other medical care components were assumed to be 
stable throughout the study period. This assumption was made 
based on an examination of MarketScan data and the opinion 
of the ELN panel. The models assumed that the average dose of 
imatinib for a given CML-CP patient would not differ before and 
after generic entry based on the opinion of the ELN panel.
All costs were expressed in 2013 US dollars using the all-
urban Consumer Price Index inflation calculator (US Bureau 
of Labor and Statistics, www.bls.gov/cpi) and discounted at 3% 
Table 1. US societal health utilities for patients with chronic myeloid 
leukemia derived from the published literature
Disease status
QALYs* (range 
for sensitivity  
analyses) Description
CP, responding  
to treatment
0.89 (0.78–0.94) CCyR
CP, not responding  
to treatment
0.75 (0.57–0.85) At diagnosis; or lack of  
CCyR leading to switch
AP, responding  
to treatment
0.79 (0.62–0.88) Szabo 2010
BP, responding  
to treatment
0.59 (0.4–0.72) Szabo 2010
BP, not responding  
to treatment
0.22 (0.07–0.34) Szabo 2010
Treatment changed  
because of serious 
adverse events
0.58 (0.38–0.76) Switch from first  
TKI to another
Allogeneic  
transplantation  
(within 1 y)
0.6 (0.51–0.69) Szabo 2010
Allogeneic  
transplantation  
(after 1 y)
0.85 (0.723–0.978) Szabo 2010
MMR 0.9 (0.765–0.99) Szabo 2010
Death 0 Anchor
* Quality-adjusted life-years (QALYs) are extracted from Szabo et al. (2010). 
They relate to this analysis as the health utility weights derived from the 
EQ5D index from the US societal perspective and represent measures of ef-
fectiveness in this analysis. In general, QALYs range from 0.0 to 1.0, where 0.0 
represents death and 1.0 represents full health over one year. This range should 
be incremental, such that 0.5 QALY is exactly ½ of full health. AP = accelerated 
phase; BP = blast phase; CP = chronic phase; MMR = major molecular response; 
QALYs = quality-adjusted life-years; TKI = tyrosine kinase inhibitor.
Table 2. Per-patient, per-month costs of treatment by TKI estimated 
from a cohort of US patients with chronic myeloid leukemia observed 
in Truven’s MarketScan claims database (2011–2012; 2013 $USD)
Monthly  
treatment costs*
Median 
cost, $
Mean cost  
(95% CI), $
Imatinib (n = 2616)
 Direct outpatient costs 11.22 696.25 (565.65 to 826.86)
 Direct inpatient costs 0 1963.48 (440.88 to 3486.08)
 Direct drug payments 5032.50 4652.59 (4456.98 to 4848.20)
Dasatinib (n = 1284)
 Direct outpatient costs 103.57 700.97 (575.02 to 826.92)
 Direct inpatient costs 0 647.21 (155.45 to 1138.97)
 Direct drug payments 7944.80 6328.27 (5981.25 to 6675.29)
Nilotinib (n = 864)
 Direct outpatient costs 111.65 634.81 (477.65 to 791.97)
 Direct inpatient costs 0 365.26 (40.92 to 689.60)
 Direct drug payments 7636.96 6287.03 (5866.54 to 6707.52)
* All data were extracted from Truven MarketScan using a sample of 397 
patients (4764 patient-months). CI = confidence interval; TKI = tyrosine kinase 
inhibitor.
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annually. Results reported per-patient, per-month costs aggre-
gated and expressed as total annual per-patient costs.
Analytic Plan
Markov models were constructed to compare the cost-effective-
ness of two treatment strategies for a cohort of incident patients 
with CML-CP enrolled over five years beginning in January 2016 
with follow-up through December 2020 (Figure 1) using TreeAge 
Pro Suite (TreeAge Software Inc, Williamstown, MA). The models 
compared two strategies: 1) standard care by physician’s choice, 
initiating newly diagnosed CML-CP treatment with any one of 
the 3 TKIs, and 2) initially using generic imatinib in all patients 
and then altering therapy as clinically required in a stepwise 
approach.
In the physician’s choice strategy, it was assumed that each 
TKI would command equal probability, or one-third of front-line 
CML treatment based on the observed distribution of TKI use in 
the MarketScan data. In both strategies, patients were assumed 
to switch once to a second-generation TKI in equal proportion 
if they failed to meet efficacy measures by the appropriate time 
points defined by ELN guidelines and based on the opinion of the 
ELN panel. The model included an additive probability that 15% 
of patients who were intolerant to one second-generation TKI 
would switch to generic imatinib, which is a less potent ABL1 
kinase inhibitor based on observed switches in the MarketScan 
data and the opinion of the ELN panel (Table 4).
The cost-effectiveness of the alternative treatment strategies 
was estimated using two distinct Markov models, one for each effi-
cacy measure described above. Details of each Markov model are 
described in the Supplementary Methods (available online). Results 
were interpreted as incremental cost-effectiveness ratios (ICERs) at 
a willingness-to-pay (WTP) threshold of $100 000 per QALY.
Sensitivity Analyses
Univariate and multivariable sensitivity analyses tested param-
eters with the greatest impact on results, including treatment 
heterogeneity based on the patient Sokal score for risk, prob-
abilities of reaching a positive CCyR or EMR, and ranges in 
the expected price drop of imatinib (see the Supplementary 
Methods, available online) (5). A Bayesian multivariable proba-
bilistic sensitivity analysis (PSA) was performed using 10 000 
Monte Carlo simulations; gamma distributions were applied to 
costs, and beta distributions for probabilities and utilities. The 
PSA was used to randomly select parameter values from their 
assumed distributions in order to provide more realistic results 
as the outcomes may be portrayed for a population with CML-CP.
Results
MarketScan Estimates of Per-Person Costs
MarketScan cost data were from 397 patients diagnosed with 
CML-CP (Table 2). The average per-person total cost of treatment 
with branded imatinib ($79 000/year) was similar to that of 
dasatinib or nilotinib ($87 000-$92 000/year), although the mean 
annual cost of the drug itself was lower (approximately $59 000 
for imatinib compared with $76 000 for dasatinib and $75 000 for 
nilotinib). Once imatinib loses patent exclusivity, the total costs 
of imatinib-based treatment (drug plus usual medical care) are 
expected to drop to about $46 000 per year (Table 3). Per-person 
cost of CML-CP treatment is largely comprised of drug costs; 
spending on other routine care components (eg, outpatient 
office visits and diagnostic tests) is limited, and the use of more 
expensive care components (eg, hospitalizations, transplants) 
among CML-CP patients responding to TKI-based treatment is 
observed to be rare in the MarketScan cohort.
Model Estimates of Effectiveness and Cost
For both models, the clinical effectiveness derived from these 
two treatment strategies fell in a narrow range, approximately 
3.8 to 4.0 QALYs over five years. Physician’s choice was estimated 
to provide slightly higher effectiveness to patients. However, the 
cost of imatinib-first therapy was lower than the cost of physi-
cian’s choice by about $80 000 to $90 000 over five years.
Base Case Analysis
Both strategies compared with a no-alternative-treatment 
option met the willingness-to-pay threshold of $100 000 
per QALY (CCyR: imatinib-first  =  $277 401, QALYs  =  3.87, 
$/QALY = $71 679, and physician’s choice = $365 774, QALYs = 3.97, 
$/QALY = $92 135; EMR: imatinib-first = $281 107, QALYs = 3.82, 
$/QALY = $73 588, and physician’s choice = $366 819, QALYs = 3.98, 
$/QALY = $92 166). However, the imatinib-first strategy was cost-
effective compared with the current standard of care based on 
the incremental cost-effectiveness ratio. Based on 12-month 
CCyR, imatinib-first cost less over five years and offered CML 
patients only slightly fewer QALYs compared with physician’s 
choice (ICER  =  883 730)  (Table  5). Similar results were found 
using the three-month EMR model (ICER = 535 700).
Sensitivity Analysis
Imatinib-first therapy was cost-effective compared with current 
standard of care based on risk stratification by low/intermediate 
Table 3. Per-patient, per-year of treatment by TKI estimated from a 
cohort of patients with chronic myeloid leukemia observed in Tru-
ven’s MarketScan claims database (2011–2012; 2013 $USD) for model 
health states
Total annual costs after  
generic entry of imatinib*
Base case (range for  
sensitivity analyses)
12-month complete cytogenetic response
 Imatinib 1 y 79 373 (65 415–87 748)
 Imatinib 2–4 y 45 875 (37 500–54 249)
 Dasatinib 92 117 (78 300–105 935)
 Nilotinib 87 445 (74 328–100 562)
3-month BCR/ABL1 early molecular response
 Imatinib 1–3 mo 21 937 (18 646–25 228)
 Dasatinib 1–3 mo 23 029 (19 575–26 484)
 Nilotinib 1-3mo 21 861 (18 582–25 141)
 Imatinib 4–12 mo 57 436 (48 821–66 052)
 Dasatinib 4–12 mo 69 088 (58 725–79 451)
 Nilotinib 4–12 mo 65 584 (55 746–75 422)
 Imatinib 2–4 y 45 875 (38 993–52 756)
 Dasatinib 2–4 y 92 117 (78 300–105 935)
 Nilotinib 2–4 y 87 445 (74 328–100 562)
Allogeneic transplant 245 000 (125 000–300 000)
* These cost data represent the mean payer prices of drugs, rather than the 
list price, to accurately represent the US commercial payer perspective. All 
predicted cost data are based on trends according to Conti and Berndt (2014) 
and crosschecked with other published estimates of generic prices of oral 
drugs. Cost of allogeneic transplantation was drawn from Preussler (2012). All 
other costs are based on cases billed according to ICD-9; see text for a list of 
ICD-9 codes. Total costs are the sum of direct expenditures for chronic myeloid 
leukemia. TKI = tyrosine kinase inhibitor.
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or high Sokal risk scores (Table  2; Supplementary Methods, 
available online). The results were robust to changes based 
on univariate analyses of all parameters. The most sensitive 
parameters in the model were the imatinib-associated prob-
abilities of reaching a positive CCyR or EMR. The model was also 
sensitive to changes in the costs of imatinib in the first year and 
remaining years.
The PSA suggested that imatinib-first therapy was over-
whelmingly cost-effective compared with physician’s choice. 
Overall, 99.7% of simulations determined that imatinib-first 
therapy had improved net monetary benefit. Approximately 
85.1% of iterations identified imatinib-first therapy as cost-
effective, that is, less costly at a slightly lower effectiveness 
compared with standard of care and below a WTP threshold of 
$100 000 per QALY (Figure  2). In an additional 14.6% of simu-
lations, imatinib-first therapy dominated physician’s choice 
because it offered both greater utility (higher QALYs) and lower 
overall cost.
Discussion
From a US commercial payer perspective, when imatinib loses 
patent protection in 2016 and lower-cost generic drugs equiva-
lent to branded imatinib become available, it will be the most 
cost-effective initial treatment strategy for incident CML-CP 
compared with the current standard of care—physician’s choice 
of imatinib, dasatinib, or nilotinib over five years. While impor-
tant to note that imatinib-first offers slightly lower effectiveness, 
estimated QALYs for both treatment strategies fell in a narrow 
range for which differences do not appear clinically meaning-
ful (26). Furthermore, imatinib costs much less, holding greater 
value per QALY. No other alternative variations of the models 
changed the cost-effectiveness of the imatinib-first treatment 
strategy over physician’s choice. Interestingly, sensitivity results 
of both models suggested that if imatinib maintained its cur-
rent branded price for five more years, imatinib-first would still 
remain the cost-effective strategy compared with standard of 
care. These results suggest that the adoption of an imatinib-
first strategy to treat newly diagnosed CML-CP patients over the 
current standard of care when generic imatinib becomes avail-
able could translate into substantial savings for US payers. For 
a commercial insurer covering 100 incident CML-CP patients in 
2016, a generic imatinib-first strategy compared with standard 
of care would save the plan USD $9.12 million (an average of $91 
163 per patient) in direct medical costs over five years.
Our results are likely lower bounds on commercial insurer 
cost savings when generic imatinib becomes available in 
the United States. This analysis assumes the imatinib-first 
Figure 1. A simplified Markov diagram of generic imatinib-first vs physician’s choice (the current standard of care) treatment strategies for treating chronic myeloid leu-
kemia in chronic phase. Under physician’s choice, patients have equal probability of beginning on imatinib, dasatinib, or nilotinib and remain on a drug until they reach a 
chance node. The chance nodes depicted in the figure represent CCyR at 12 months (or, as noted in the Methods, EMR at 3 months). Patients have three possible outcomes 
prior to reaching the first chance node, whether at 12 months in the first CCyR model or three months in the second EMR model: remaining on TKI therapy, progressing 
to AP/BC, or death. Patients who respond positively to a TKI stay on it the remainder of time, and overall survival since progression to AP/BC or death is uncommon after 
that point. Patients who fail their initial TKI because of intolerance or lack of efficacy can switch once (*) at 12 months (or 3 months in the EMR model) to another TKI. 
Under generic imatinib-first, 100% of patients begin on imatinib and only switch to nilotinib or dasatinib because of intolerance or if a CCyR (or EMR) was not reached. 
Some patients who fail under TKI therapy transition to the AP/BC state, which includes the risk of death. *Indicates where one switch at 12 months (or 3 months) can take 
place. AP/BC = accelerated phase/blast crisis; CCyR = complete cytogenetic response; EMR = early molecular response; M = Markov node; TKI = tyrosine kinase inhibitor.
6 of 9 | JNCI J Natl Cancer Inst, 2016, Vol. 108, No. 7
a
r
t
ic
le
treatment strategy would be adopted for newly diagnosed 
CML-CP patients only. Thus, there are two types of patients with 
prevalent CML-CP excluded from the analysis: 1) those currently 
treated with nilotinib or dasatinib and 2) those who have been 
treated with branded imatinib for one year or longer and have 
responded well to treatment. The selection of generic imatinib 
for the treatment of both patient types might be affected by 
generic substitution policies implemented by pharmacies with-
out insurer or patient involvement and/or motivated by patient 
and/or insurer cost consciousness (38–40). Indeed, depending 
on the province, Canadian pharmacies are authorized (or even 
required) to switch all incident and prevalent CML patients 
using branded imatinib to either of two generic formulations of 
imatinib (40). In the United States, generic substitution by phar-
macists of oral drugs covered under a patient’s pharmacy ben-
efits is allowed or sometimes even mandated although in some 
states pharmacists must contact the prescribing physician for 
permission to substitute (40). Alternatively, physicians might 
choose to adopt this strategy based on their patients’ expressed 
cost consciousness (38), which might be related to the common 
use of formularies by insurers with differential patient out-of-
pocket copayment requirements between generic and branded 
drugs (42).
The analysis has a number of limitations. The models 
assume perfect patient adherence to TKI-based treatment 
across all treatment modalities studied and no change in TKI 
usage patterns before and after imatinib’s generic entry. These 
assumptions are subject to several caveats (44–46). For example, 
Dusetzina et al. found that among a commercially insured CML 
patient population in the United States patients with higher 
copayments were more likely to be nonadherent to imatinib-
based therapy (47). Patients with higher copayments were 42% 
more likely to be nonadherent to the recommended daily dos-
ing. Poor adherence to TKI therapy leads to unfavorable clinical 
outcomes (44–46). To the extent patient nonadherence to TKI-
based treatment is related to out-of-pocket pharmacotherapy 
costs, generic entry of imatinib may lead to better treatment 
adherence among selected patients. This limitation would bias 
results in favor of the imatinib-first strategy.
This study did not employ a lifetime time horizon. While 
this horizon is appealing from a societal perspective, such an 
analysis requires modeling assumptions regarding OS, generic 
entry dates, associated future pricing and use pattern changes 
among the competing, currently available TKIs, and CML-CP 
treatment innovation in the future. None of these param-
eters are known at this time, and the ELN expert panel was 
unable to come to consensus regarding reasonable ranges of 
values for each of these parameters for additional sensitivity 
analyses. This is an important topic for future study. Similarly, 
an important unknown is the fraction of newly diagnosed 
CML-CP patients who might eventually be able to discontinue 
TKI therapy because their disease has been suppressed to an 
undetectable level for a long time period, or perhaps even been 
cured (48–52). This treatment strategy holds great potential for 
health system cost savings, even if a more expensive TKI were 
required for several years to achieve this stopping point.
The study is also limited by lacking data about additional 
switches among first-, second-, and third-generation TKIs 
Table  4. Base case probabilities and range for sensitivity analysis 
employed in Markov models distinguished by use of the efficacy 
endpoints of complete cytogenetic response at 12 months or early 
molecular response at 3 months for newly diagnosed patients with 
chronic phase chronic myeloid leukemia enrolled on prospective 
clinical trials
12-mo CCyR 3-mo EMR
Probabilities
Base case (range  
for sensitivity analyses) Base case
Imatinib
 CCyR 0.7 (0.60–0.81) 0.65
 Not CCyR or intolerant 0.23 (0.20–0.26) Remainder
  Switch to dasatinib 0.5
   Overall survival 0.74 (0.63–0.85)
   Death* 0.26
  Switch to nilotinib 0.5
   Overall survival 0.74 (0.63–0.85)
   Death* 0.26
  AP/BC 0.07 (0.060–0.081) 0.07
   Survival 0.5 (0.43–0.58)
   Death* 0.5 (0.43–0.58)
Dasatinib
 CCyR 0.85 (0.72–0.98) 0.84
 Not CCyR or intolerant 0.1 (0.085–0.12) Remainder
  Switch to imatinib 0.15 (0.10–0.50)
   Overall survival 0.3 (0.26–0.35)
   Death* 0.7
  Switch to nilotinib* 0.85
   Overall survival 0.3 (0.26–0.35)
   Death* 0.7
  AP/BC 0.05 (0.043–0.058) 0.05
   Survival 0.5 (0.43–0.58)
   Death* 0.5 (0.43–0.58)
Nilotinib
 CCyR 0.8 (0.68–0.92) 0.9
 Not CCyR or intolerant 0.16 Remainder
  Switch to imatinib 0.15 (0.10–0.50)
   Overall survival 0.75 (0.64–0.86)
   Death* 0.25
  Switch to dasatinib* 0.85
   Overall survival 0.75 (0.64–0.86)
   Death* 0.25
  AP/BC 0.04 (0.034–0.046) 0.04
   Survival 0.5 (0.43–0.58)
   Death* 0.5 (0.43–0.58)
* Indicates remainder probability, adding up to 1.0 for all subnodes. Indenta-
tions in the listing of model parameters above are representative of the Markov 
model subnodes in Figure 1. Full description of related model probabilities 
is available in the Supplementary Materials (available online). Data were 
extracted from a meta-analysis of published clinical trial results (1–9,19–25). 
AP/BC = accelerated phase/blast crisis; CCyR = complete cytogenetic response; 
CML = chronic myeloid leukemia; EMR = early molecular response.
Table 5. Base-case results of cost utility analysis based on two Mark-
ov models distinguished by use of the efficacy endpoints of complete 
cytogenetic response at 12 months or early molecular response at 
3 months; the ICERs are largely driven by cost differences because 
there are no clinically significant differences between the measures 
of effectiveness*
Treatment Cost, $
Effectiveness, 
QALYs
ICER, $/ 
QALY
12-month complete cytogenetic response
 Imatinib-first  277 401  3.87
 Physician’s choice  365 774  3.97  883 730
3-month BCR/ABL1 early molecular response
 Imatinib-first  281 107  3.82
 Physician’s choice  366 819  3.98  535 700
* ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.
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following three- or 12-month efficacy/tolerability endpoints. 
The study derived outcomes and the achievement of efficacy 
and tolerance milestones based on a systematic review of 
randomized controlled clinical trial results that only followed 
patients through one possible switch related to initial TKI-
associated lack of efficacy or intolerance. This omission does 
not substantially bias these results because switching between 
one currently available second-generation TKI to another or a 
third-generation TKI would have little impact on treatment 
costs given the largely equivalent current market prices of these 
branded drugs. Patients who switch to a third TKI because of 
lack of efficacy or intolerance are often candidates for alloge-
neic transplantation, which was included in the models. More 
generally, results may not apply to patients with comorbidities, 
older age, or lack of access to appropriate specialty care who 
would have been excluded from the clinical trials upon which 
this analysis is based.
In 2016, we anticipate that the per-patient, per-month cost 
of imatinib will drop 60% to 90% once it loses patent protection 
while second generation TKIs dasatinib and nilotinib will hold 
their high costs steady. From a US payer perspective, imatinib 
will be the cost-effective initial treatment strategy for CML-CP 
compared with dasatinib and nilotinib.
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